Moffitt Cancer Center and Aptose Biosciences to Present Data on a Novel Class of Dual-Targeting Bromodomain / Kinase Inhibitors at 57th Annual American Society of Hematology (ASH) Meeting Dec 03, 2015 8:00am EST
Aptose Voluntarily Suspends Clinical Dosing of APTO-253 to Review Drug Manufacturing Processes and Procedures Nov 20, 2015 7:30am EST
Aptose Biosciences Reports Results for the Third Quarter Ended September 30, 2015 Nov 10, 2015 4:05pm EST
Aptose Biosciences Announces Collaborations for New Multi-Targeting Epigenetic Therapeutic Agents Nov 10, 2015 8:30am EST
Beat AML & Aptose Biosciences Present Data for APTO-253 at the 57th American Society of Hematology (ASH) Annual Meeting Nov 05, 2015 9:15am EST
Aptose Biosciences to Host Third Quarter Ended September 30, 2015 Financial Results Conference Call and Webcast Nov 05, 2015 8:00am EST
Aptose Biosciences to Present at Canaccord Genuity 35th Annual Growth Conference Aug 10, 2015 8:00am EDT
